Literature DB >> 27799354

Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus Infection.

Christine Dahlke1,2, Sebastian Lunemann3, Rahel Kasonta1,2, Benno Kreuels1, Stefan Schmiedel1, My L Ly1,2, Sarah K Fehling4,5, Thomas Strecker4,5, Stephan Becker4,5, Marcus Altfeld6,2, Abdourahmane Sow7, Ansgar W Lohse1,2, César Muñoz-Fontela3, Marylyn M Addo1,2.   

Abstract

The West African Ebola virus disease (EVD) outbreak was the largest EVD outbreak in history. However, data on lymphocyte dynamics and the antigen specificity of T cells in Ebola survivors are scarce, and our understanding of EVD pathophysiology is limited. A case of EVD survival in which the patient cleared Ebola virus (EBOV) infection without experimental drugs allowed for the detailed examination of lymphocyte dynamics. We demonstrate the persistence of T-cell activation well beyond viral clearance and detect EBOV-specific T cells. Our study provides significant insights into lymphocyte specificity during the recovery phase of EVD and may inform novel strategies to treat EVD.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  EVD; EVD survivor; Ebola GP–specific T-cell responses; T-cell activation; cellular immune response; convalescent phase; lymphocyte dynamics; polyfunctional T-cell responses

Mesh:

Year:  2017        PMID: 27799354     DOI: 10.1093/infdis/jiw508

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans.

Authors:  Emily Speranza; Paula Ruibal; Julia R Port; Feng Feng; Lia Burkhardt; Adam Grundhoff; Stephan Günther; Lisa Oestereich; Julian A Hiscox; John H Connor; César Muñoz-Fontela
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

2.  A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.

Authors:  Bobby Brooke Herrera; Donald J Hamel; Philip Oshun; Rolake Akinsola; Alani S Akanmu; Charlotte A Chang; Philomena Eromon; Onikepe Folarin; Kayode T Adeyemi; Christian T Happi; Yichen Lu; Folasade Ogunsola; Phyllis J Kanki
Journal:  PLoS Negl Trop Dis       Date:  2018-05-24

3.  Long-lasting severe immune dysfunction in Ebola virus disease survivors.

Authors:  Aurélie Wiedemann; Emile Foucat; Hakim Hocini; Cécile Lefebvre; Boris P Hejblum; Mélany Durand; Miriam Krüger; Alpha Kabinet Keita; Ahidjo Ayouba; Stéphane Mély; José-Carlos Fernandez; Abdoulaye Touré; Slim Fourati; Claire Lévy-Marchal; Hervé Raoul; Eric Delaporte; Lamine Koivogui; Rodolphe Thiébaut; Christine Lacabaratz; Yves Lévy
Journal:  Nat Commun       Date:  2020-07-24       Impact factor: 14.919

4.  Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.

Authors:  Yap Boum; Aitana Juan-Giner; Matt Hitchings; Aboubacar Soumah; Thomas Strecker; Mariama Sadjo; Hannah Cuthbertson; Peter Hayes; Marie Tchaton; Jean-Paul Jemmy; Carolyn Clarck; Deborah King; Elisabetta Maria Faga; Stephan Becker; Bassam Halis; Norheim Gunnstein; Miles Carroll; John-Arne Røttingen; Mandy Kader Kondé; Moise Doumbia; Ana-Maria Henao-Restrepo; Marie-Paule Kieny; Mohamed Cisse; Bertrand Draguez; Rebecca F Grais
Journal:  Vaccine       Date:  2020-06-01       Impact factor: 3.641

5.  Virus-Vectored Ebola Vaccines.

Authors:  I V Dolzhikova; E A Tokarskaya; A S Dzharullaeva; A I Tukhvatulin; D V Shcheblyakov; O L Voronina; S I Syromyatnikova; S V Borisevich; V B Pantyukhov; V F Babira; L V Kolobukhina; B S Naroditsky; D Y Logunov; A L Gintsburg
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845

6.  Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.

Authors:  Christine Dahlke; Rahel Kasonta; Sebastian Lunemann; Verena Krähling; Madeleine E Zinser; Nadine Biedenkopf; Sarah K Fehling; My L Ly; Anne Rechtien; Hans C Stubbe; Flaminia Olearo; Saskia Borregaard; Alen Jambrecina; Felix Stahl; Thomas Strecker; Markus Eickmann; Marc Lütgehetmann; Michael Spohn; Stefan Schmiedel; Ansgar W Lohse; Stephan Becker; Marylyn M Addo
Journal:  EBioMedicine       Date:  2017-04-05       Impact factor: 8.143

Review 7.  Exploring the Immunopathogenesis of Viral Hemorrhagic Fever in Mice with a Humanized Immune System.

Authors:  Günther Schönrich; Martin J Raftery
Journal:  Front Immunol       Date:  2017-09-26       Impact factor: 7.561

8.  Variation around the dominant viral genome sequence contributes to viral load and outcome in patients with Ebola virus disease.

Authors:  Xiaofeng Dong; Jordana Munoz-Basagoiti; Natasha Y Rickett; Georgios Pollakis; William A Paxton; Stephan Günther; Romy Kerber; Lisa F P Ng; Michael J Elmore; N'faly Magassouba; Miles W Carroll; David A Matthews; Julian A Hiscox
Journal:  Genome Biol       Date:  2020-09-07       Impact factor: 13.583

9.  Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease.

Authors:  Romy Kerber; Ralf Krumkamp; Misa Korva; Toni Rieger; Stephanie Wurr; Sophie Duraffour; Lisa Oestereich; Martin Gabriel; Daouda Sissoko; Xavier Anglaret; Denis Malvy; Jürgen May; Tatjana Avšic Županc; César Muñoz-Fontela; Stephan Günther
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.